Melanoma following treatment with alemtuzumab for multiple sclerosis
- 19 March 2009
- journal article
- Published by Wiley in European Journal of Neurology
- Vol. 16 (4) , e70-e71
- https://doi.org/10.1111/j.1468-1331.2009.02552.x
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Alemtuzumab vs. Interferon Beta-1a in Early Multiple SclerosisNew England Journal of Medicine, 2008
- More on Melanoma with TransdifferentiationNew England Journal of Medicine, 2008
- Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosisZeitschrift für Neurologie, 2008
- Melanoma Complicating Treatment with Natalizumab for Multiple SclerosisNew England Journal of Medicine, 2008
- Malignant melanoma in a multiple sclerosis patient with persistent neutralizing antibodies to interferon‐betaEuropean Journal of Neurology, 2007
- High affinity interaction of integrin α4β1 (VLA‐4) and vascular cell adhesion molecule 1 (VCAM‐1) enhances migration of human melanoma cells across activated endothelial cell layersJournal of Cellular Physiology, 2007
- Routine clinical use of alemtuzumab in patients with heavily pretreated B‐cell chronic lymphocytic leukemiaCancer, 2006
- The window of therapeutic opportunity in multiple sclerosisZeitschrift für Neurologie, 2005